0 CHECKOUT

Premenstrual Syndrome - Pipeline Review, H2 2015

  • ID: 3384923
  • July 2015
  • 41 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • DEKK-TEC, Inc.
  • M et P Pharma AG
  • Umecrine Mood AB
  • MORE

Premenstrual Syndrome - Pipeline Review, H2 2015

Summary

The report ‘Premenstrual Syndrome - Pipeline Review, H2 2015’, provides an overview of the Premenstrual Syndrome’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Premenstrual Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Premenstrual Syndrome and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • DEKK-TEC, Inc.
  • M et P Pharma AG
  • Umecrine Mood AB
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Premenstrual Syndrome Overview
Therapeutics Development
Pipeline Products for Premenstrual Syndrome - Overview
Pipeline Products for Premenstrual Syndrome - Comparative Analysis
Premenstrual Syndrome - Therapeutics under Development by Companies
Premenstrual Syndrome - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Premenstrual Syndrome - Products under Development by Companies
Premenstrual Syndrome - Companies Involved in Therapeutics Development
Azevan Pharmaceuticals, Inc.
DEKK-TEC, Inc.
M et P Pharma AG
Pherin Pharmaceuticals, Inc.
Umecrine Mood AB
Premenstrual Syndrome - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
PH-80PMD - Drug Profile
Product Description
Mechanism of Action
R&D Progress
progesterone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
progesterone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule-1 to Antagonize GABAA Receptor for PMDD - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule-2 to Antagonize GABAA Receptor for PMDD - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SRX-251 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
UC-1010 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Premenstrual Syndrome - Recent Pipeline Updates
Premenstrual Syndrome - Product Development Milestones
Featured News & Press Releases
Sep 19, 2014: Umecrine Mood announces positive results from an exploratory Phase I/II study with UC1010 in premenstrual dysphoric disorder (PMDD)
Jun 12, 2014: Umecrine Mood reports preliminary data from exploratory Phase II study in premenstrual dysphoric disorder
Dec 16, 2013: Patient recruitment completed in the Phase I/II study of Umecrine Mood’s candidate drug for severe premenstrual symptoms
May 23, 2013: Umecrine Mood Announces Dosing Of First Patient In Phase I/II Study Of UC1010 For Premenstrual Dysphoric Disorder
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Premenstrual Syndrome, H2 2015
Number of Products under Development for Premenstrual Syndrome - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Premenstrual Syndrome - Pipeline by Azevan Pharmaceuticals, Inc., H2 2015
Premenstrual Syndrome - Pipeline by DEKK-TEC, Inc., H2 2015
Premenstrual Syndrome - Pipeline by M et P Pharma AG, H2 2015
Premenstrual Syndrome - Pipeline by Pherin Pharmaceuticals, Inc., H2 2015
Premenstrual Syndrome - Pipeline by Umecrine Mood AB, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Premenstrual Syndrome Therapeutics - Recent Pipeline Updates, H2 2015

List of Figures
Number of Products under Development for Premenstrual Syndrome, H2 2015
Number of Products under Development for Premenstrual Syndrome - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Azevan Pharmaceuticals, Inc.
DEKK-TEC, Inc.
M et P Pharma AG
Pherin Pharmaceuticals, Inc.
Umecrine Mood AB

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Pfizer Inc.
  • Grünenthal GmbH
  • GlaxoSmithKline PLC
  • Abbott Laboratories Ltd.
  • Roche Diagnostics Ltd.
  • Novo Nordisk A/S